Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-18T17:18:00.041Z Has data issue: false hasContentIssue false
  • English
  • Français

Guilt and depression: Two different factors in individuals with negative symptoms of schizophrenia

Published online by Cambridge University Press:  15 April 2020

L. Rabany ,
M. Weiser  and
Y. Levkovitz
L. Rabany*
Affiliation:
Gordon Faculty of Social Sciences, Tel-Aviv University, Tel-Aviv, Israel Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel The Emotion-Cognition Research Center, The Shalvata Mental Health Care Center, PO Box 94, Hod-Hasharon, Israel
M. Weiser
Affiliation:
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel Department of Psychiatry, Sheba Medical Center, Ramat-Gan, Israel
Y. Levkovitz
Affiliation:
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel The Emotion-Cognition Research Center, The Shalvata Mental Health Care Center, PO Box 94, Hod-Hasharon, Israel Massachusetts General Hospital, Boston, United States
*
*Corresponding author. Tel.: +972 9 9798644; fax: +972 9 9798643. E-mail address:[email protected] (L. Rabany).
Get access

Abstract

Objective:

Depression is common among schizophrenia patients and constitutes a major risk factor for suicide. Calgary Depression Scale (CDSS) is the most widely used instrument for measuring depression in schizophrenia. CDSS has never been examined in patients with predominant negative symptoms, thus possibly hindering both accurate assessment and understanding of the underlying mechanisms. The current study is the first to examine CDSS’ structure in this population.

Methods:

We conducted Principal Component Analysis (n = 184) for the CDSS items. Thereafter, we correlated emerging factors with psychopathological, demographic and side effect variables. We assessed internal consistency and reliability of the emerging factors, as well as demographic correlations.

Results:

The analysis yielded two factors: depression-hopelessness and guilt. Factors distinctly correlated with separate variables. Removal of item #7 (early waking) improved internal consistency. The depression-hopelessness factor had an inverse correlation with negative symptoms, and positive correlation with neuroleptic side effects.

Conclusions:

CDSS structure indicated of two separate factors, i.e., depression-hopelessness and guilt, suggesting separate underlying processes. The validity of the scale might benefit from a two-fold structure and the removal/replacement of item #7 (early waking). A noteworthy inverse correlation was found between the depression factor and negative symptoms, as well as a positive correlation between depression factor and neuroleptic side effects.

Keywords

SchizophreniaCalgary Depression Scale (CDSS)DepressionFactor analysisPositive and Negative Symptom Scale (PANSS)
Type
Original article
Information
European Psychiatry , Volume 28 , Issue 6 , August 2013 , pp. 327 - 331
Copyright
Copyright © European Psychiatric Association

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Addington, DAddington, JAtkinson, MA psychometric comparison of the Calgary Depression Scale for schizophrenia and the Hamilton Depression Rating Scale. Schizophr Res 1996;19:205–212.CrossRefGoogle ScholarPubMed
Addington, DAddington, JMaticka-Tyndale, EAssessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry 1993;Supplement:39.CrossRefGoogle ScholarPubMed
Davis, JChen, NGlick, IA meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553.CrossRefGoogle ScholarPubMed
Fennig, SEverett, EBromet, EJ, et al.Insight in first-admission psychotic patients. Schizophr Res 1996;22:257–263.CrossRefGoogle ScholarPubMed
Fenton, WSMcGlashan, THVictor, BJ, et al.Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Am J Psychiatry 3;154(2):199–204.Google Scholar
Guy, WAbnormal involuntary movement scale (AIMS). ECDEU assessment manual for psychopharmacology 1976;338:534–537.Google Scholar
Hamilton, MA rating scale for depression. Br Med J 1960;23:56.Google ScholarPubMed
Harrow, MYonan, CSands, J, et al.Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved?. Schizophr Bull 1994;20:327.CrossRefGoogle ScholarPubMed
Herz, MProdromal symptoms and prevention of relapse in schizophrenia. J Clin Psychiatry 1985;46:22–25.Google Scholar
Kay, SFiszbein, AOpler, LThe positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261.CrossRefGoogle Scholar
Kirkpatrick, BBuchanan, RWBreier, A, et al.Depressive symptoms and the deficit syndrome of schizophrenia. J Nerv Ment Dis 1994;182:452.CrossRefGoogle ScholarPubMed
Krakowski, MCzobor, PVolavka, JEffect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes. Psychiatry Res 1997;71:19–26.CrossRefGoogle ScholarPubMed
Lancon, CAuquier, PReine, G, et al.Study of the concurrent validity of the Calgary Depression Scale for Schizophrenics (CDSS). J Affect Disord 2000;58:107–115.CrossRefGoogle Scholar
Maggini, CRaballo, AExploring depression in schizophrenia. Eur Psychiatry 2006;21:227–232.CrossRefGoogle Scholar
Moller, HAntidepressive effects of traditional and second generation antipsychotics: a review of the clinical data. Eur Arch Psychiatry Clin Neurosci 2005;255:83–93.CrossRefGoogle ScholarPubMed
Moller, HRiedel, MJager, MWickelmaier, FMaier, WKuhn, K, et al.Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int J Neuropsychopharmacol 2008;11:985–997.CrossRefGoogle ScholarPubMed
Perenyi, ANorman, THopwood, M, et al.Negative symptoms, depression and parkinsonian symptoms in chronic, hospitalised schizophrenic patients. J Affect Disord 1998;48:163–169.CrossRefGoogle ScholarPubMed
Perkins, DHongbin, GWeiden, P, et al.Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry 2008;69:106–113.CrossRefGoogle ScholarPubMed
Purdon, SJones, BStip, E, et al.Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 2000;57:249.CrossRefGoogle ScholarPubMed
Rabany, LWeiser, MWeberloff, N, et al.Assessment of negative symptoms and depression in schizophrenia: revision of the SANS and how it relates to the PANSS and CDSS. Schizophr Res 2010;126:226–230.CrossRefGoogle ScholarPubMed
Resnick, SRosenheck, RLehman, AAn exploratory analysis of correlates of recovery. Psychiatr Serv 2004;55:540.CrossRefGoogle ScholarPubMed
Schwartz-Stav, OApter, AZalsman, GDepression, suicidal behavior and insight in adolescents with schizophrenia. Eur Child Adolesc Psychiatry 2006;15:352–359.CrossRefGoogle ScholarPubMed
Simpson, GA rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;45:11–19.CrossRefGoogle Scholar
Tollefson, GAndersen, SShould we consider mood disturbance in schizophrenia as an important determinant of quality of life?. J Clin Psychiatry 1999;60:23–29.Google ScholarPubMed
Yon, VLoas, GSymptomatologie subjective et schizophrénie. Relationships between subjective experience of deficit and other psychopathological features. Elsevier; 1999. p. 12–9.Google Scholar
Zisook, SMcAdams, LKuck, J, et al.Depressive symptoms in schizophrenia. Am J Psychiatry 1999;156:1736.Google Scholar
Submit a response

Comments

No Comments have been published for this article.